Proactive Investors - Run By Investors For Investors

MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments

The company has partnered with Precision Biosciences of the US
MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments
MaxCyte's new partner has developed the ARCUS gene editing platform

MaxCyte PLC (LON:MXCT) has negotiated a clinical and commercial licence deal with Precision Biosciences of the US.

Under the terms of the agreement, Precision will use MaxCyte's flow electroporation cell engineering technology alongside its own ARCUS genome-editing platform.  

The plan is to develop the next generation of cell-based therapies for cancer.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma​

"Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems,” said its chief development officer David Thomson.

“In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximising overall yield."

Building on earlier deal 

The new tie-up builds on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said MaxCyte chief executive Doug Doerfler.

The AIM-listed life sciences group’s flow electroporation technology allows cells to be re-engineered efficiently, with high viability and recovery.

Precision will use its ARCUS gene editing tools and the MaxCyte’s breakthrough to transform donor cells into immunotherapies such CAR-T cells.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use